One year with EU HTA: what are the learnings in a Norwegian setting

Join us for an insightful morning seminar where we take stock of the first year of EU HTA implementation and explore its practical implications for market access, decision-making, and patient access in Norway. This event is designed for life science professionals who want to move beyond theory and understand how the regulation is playing out in real life.

You will gain insights into:

• Key learnings from the first year of EU HTA implementation
• How EU HTA is influencing national processes and assessments
• Implications for pharmaceutical and biotech companies operating in Norway
• What these developments may mean for future access to innovative therapies

The session will feature perspectives from regulatory authorities, industry, and European policy, followed by a summary discussion.

Programme
08:30–09:00 Coffee and breakfast
09:00–09:15 Welcome and introduction
09:15–10:15 One year with EU HTA – learnings in a Norwegian setting
10:15–10:30 Summary and closing

Speakers:

Hilde Roshold, Senior Advisor, DMP
Herbert Altmann, Vice President, Cencora – EU Market Access
Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE
Representative from a patient organization

Places are limited. We encourage early registration.

We look forward to welcoming you to a thought-provoking morning of insights, discussion, and networking.

Sign up here.